Ignite Creation Date:
2024-06-16 @ 11:48 AM
Last Modification Date:
2024-10-26 @ 3:30 PM
Study NCT ID:
NCT06429943
Status:
COMPLETED
Last Update Posted:
2024-05-28
First Post:
2024-05-21
Brief Title:
Cerebrolysin in SAH Subarachnoidal Haemorrhage - Observational Study
Sponsor:
Pomeranian Medical University Szczecin
Organization:
Pomeranian Medical University Szczecin
Study Overview
Official Title:
Cerebrolysin in Patients Diagnosed With SAH - an Observational Cohort Study PILOT
Status:
COMPLETED
Status Verified Date:
2023-12
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
Subarachnoid haemorrhage often affects people in middle age and is associated with high mortality or neurological damage In recent years advances in surgical techniques have im-proved the mortality rate However there is still need for the research for the optimal possible final effect of treatment In our study weve decided to examine the effect of a multimodal approach including Cerebrolysin in the supportive treatment of patients Weve examined the supply of neuroprotective drugs and neuromonitoring
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
False
Is a FDA Regulated Device?:
False
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
False
Is an FDA AA801 Violation?:
None